Shares of Iovance Biotherapeutics are up 19% or $1.76 at $10.91 afterhours following the company’s conference call about Amtagvi’s accelerated approval from the FDA and commentary that the Amtagvi black box label “looks pretty good”.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IOVA:
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024
- Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma
- Iovance Biotherapeutics call volume above normal and directionally bullish
- Unusually active option classes on open January 26th
